Algert Global’s Dianthus Therapeutics DNTH Stock Holding History

Algert Global’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.73M	Sell	44,398 -85,928	-66%	-$4.98M	0.06%	526
2025 Q4	$5.37M	Buy	+130,326	New	+$5.05M	0.08%	408
2021 Q4	–	Sell	-939	Closed	-$109K	–	1001
2021 Q3	$109K	Sell	939 -558	-37%	-$65K	0.01%	960
2021 Q2	$234K	Sell	1,497 -1,177	-44%	-$216K	0.08%	330
2021 Q1	$507K	Buy	2,674 +350	+15%	+$58.9K	0.16%	201
2020 Q4	$291K	Sell	2,324 -617	-21%	-$70K	0.08%	301
2020 Q3	$320K	Buy	2,941 +2,210	+302%	+$262K	0.1%	245
2020 Q2	$88K	Buy	+731	New	+$103K	0.03%	380
2019 Q4	–	Sell	-784	Closed	-$129K	–	398
2019 Q3	$129K	Buy	+784	New	+$149K	0.05%	310

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Algert Global's DNTH Position: Q1 2026 in Review

Algert Global reduced its Dianthus Therapeutics (DNTH) stake by 66% in Q1 2026, selling an estimated $4.98M and leaving 44,398 shares worth $3.73M. The position accounts for 0.06% of the portfolio, ranked #526.

Algert Global first reported a position in DNTH in Q3 2019 and has held it in 9 quarters since. The position peaked at $5.37M in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

Algert Global held 44,398 shares of Dianthus Therapeutics worth $3.73M as of Q1 2026.
Algert Global sold 85,928 Dianthus Therapeutics shares in Q1 2026, an estimated $4.98M.
Dianthus Therapeutics made up 0.06% of Algert Global's portfolio in Q1 2026, its #526 holding.
Algert Global first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 9 quarters since.
Algert Global's Dianthus Therapeutics position peaked at $5.37M in Q4 2025.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.